895 / 1851
TREATMENT:
1. HD-MTX + Procarbazine + Ara-C
2. Eventual WBI: 45 Gy
30% of patients developed treatment-related
neurotoxicity after WBI.
1. Pts >60 years: 75% (9/12).
2. Pts <60 years: 26% (5/19).
Only one patient developed neurotoxicity after
chemotherapy alone; this patient had an initial KPS
of 40 with poor recovery of function and possible
MTX- induced leukoencephalopathy.
The median survival from diagnosis of neurotoxicity
was 23 months.
Overall population
N.B. formal neuropsychological testing was not performed